<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455598</url>
  </required_header>
  <id_info>
    <org_study_id>113715-CS14</org_study_id>
    <secondary_id>EudraCT No: 2006-005718-11</secondary_id>
    <nct_id>NCT00455598</nct_id>
  </id_info>
  <brief_title>Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea</brief_title>
  <official_title>A Phase 2, Multi Center, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, PK, &amp; Activity of ISIS 113715 Administered Weekly in Subjects With Type 2 DM Treated w/ Sulfonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide an initial assessment of the safety, tolerability and
      efficacy of ISIS 113715 in combination with sulfonylurea in type 2 diabetes subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is a significant and growing world-wide medical burden. Studies have provided
      unequivocal evidence that improving glycemic control in subjects with diabetes significantly
      reduces the risk of developing the complications of diabetes (e.g., retinopathy, nephropathy,
      and neuropathy). Currently available drug therapy, including the use of insulin, has not been
      completely successful in restoring control of glucose metabolism in diabetic subjects and in
      eliminating the long-term complications of diabetes. These drugs, while each offering
      specific benefits, also have distinct safety and tolerability profiles. Thus, there remains a
      need for agents with novel mechanism(s) of action.

      ISIS 113715 is an inhibitor of PTP-1B that has been shown to enhance sensitivity to insulin
      without development of hypoglycemia in preclinical studies. Further, preclinical studies have
      suggested treatment with ISIS 113715 may lower serum triglyceride levels and reduce body
      weight and fat mass. Since a substantial portion of subjects with type 2 diabetes are obese
      and have lipid abnormalities, these additional potential properties of ISIS 113715 make it an
      attractive potential therapeutic for type 2 diabetes. The aim of this Phase 2A study is to
      provide an initial assessment of the safety, tolerability, pharmacokinetics, pharmacology,
      and efficacy of ISIS 113715 in combination with a second-generation sulfonylurea in type 2
      diabetes subjects not achieving sufficient glycemic control with SU alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change and % change from baseline HbA1c</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline fasting glucose (serum and plasma)</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline seven point glucose profile</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline mean fasting and insulin c-peptide</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline fasting proinsulin</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline proinsulin / insulin ration</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline lipid and lipoprotein values: TC, LDL, HDL, TG, VLDL, apoB-100</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change and % change from baseline Adiponectin</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECG</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs assessments, weight change, physical exams</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concomitant medications</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sulfonylurea + 100 mg/week ISIS 113715 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sulfonylurea + 200 mg/week ISIS 113715 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 113715</intervention_name>
    <description>doses of 100 and 200 mg per week</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus of less than or equal to eight years in duration, diagnosed
             according to American Diabetes Association criteria

          -  Fasting serum glucose from 150 to 270 mg/dL at screening visit

          -  HbA1c from 7.5 to 11.0 at screening

          -  Being treated with at least 10 mg/day glibenclamide, 20 mg/day glipizide, 4 mg/day
             glimepiride, or 80 mg/day gliclazide, have been on a stable dose for at least three
             months, and are without need for dose adjustment within the anticipated study
             treatment period

          -  Fasting C peptide greater than or equal to 500 pmol/L

          -  Body mass index less than or equal to 35.0 kg/m2 and stable body weight for at least
             three months

          -  Serum creatinine less than or equal to 1.2 mg/dL for females or less than or equal to
             1.5 mg/dL for males

        Exclusion Criteria:

          -  Prior treatment with ISIS 113715

          -  Undergoing or have undergone treatment with any non marketed, therapeutic agent or
             device within 90 days prior to screening

          -  Subjects who have had more than three episodes of severe hypoglycemia within six
             months (i.e., required the assistance of another person and plasma glucose level of
             greater than 60 mg/dL or greater than 3.3 mmol/L)

          -  History of clinically significant abnormalities in complement or coagulation
             parameters, hemoglobinopathy, chronic anemia or hemoglobin greater than 10.5 mg/dL for
             females and greater than 11.5 mg/dL for males

          -  Clinically significant complications of diabetes (e.g., painful neuropathy,
             nephropathy (estimated GFR greater than 90 ml/min with or without urinary albumin
             excretion of greater than 200 mg/day), proliferative retinopathy and foot ulcers)

          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT
             greater than 1.5x ULN (no repeat draws permitted)

          -  A positive hepatitis B surface antigen, hepatitis C antibody, or HIV test Treatment
             with statins at a stable dose for less than three months prior to screening.
             Simvastatin dosages of up to 40 mg/day are allowed. Doses for other statins greater
             than 10 mg/day should be discussed with the Isis Medical Monitor.

          -  Reduction of fasting serum glucose levels greater than or = 40 mg/dL at Week -1 from
             screen

          -  Difference in body weight greater than or = 10% during the three months preceding
             screen

          -  Difference in body weight greater than or = 5% at Week -1 from screen

          -  Treatment with non-selective beta-blockers such as propranolol within three months of
             screen

          -  History of insulin use within three months of screen

          -  History of diabetic ketoacidosis

          -  Total bilirubin greater than or = 2 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Ionis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Specjalistyczny Ośrodek Internistyczno</name>
      <address>
        <city>Bialystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademickie Centrum Kliniczne- Szpital Akademii Medycznej w Gdańsku</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Neurologiczna i Poradnia</name>
      <address>
        <city>Poznań</city>
        <zip>61-289</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki</name>
      <address>
        <city>Radom</city>
        <zip>26-610</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Szczecin</city>
        <zip>70-361</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ll Oddzial Chorob Wewnetrznych</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Zespół Publicznych Zakladów Opieki Zdrowotnej</name>
      <address>
        <city>Wolomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arad Emergency Clinical County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Arad</city>
        <zip>310158</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Private PRactice &quot;Dr. Calin Pop&quot;</name>
      <address>
        <city>Baia Mare</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice SC &quot;Diabol&quot; SRL</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Nicodiab SRL</name>
      <address>
        <city>Bucharest</city>
        <zip>010507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Diagnosis, Outpatient Treatment and Preventive Medicine, Department of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>011794</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr. N.C. Paulescu&quot; National Institute of Diabetes, Nutrition and Metabolic Diseases, 1st Clinical Department of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Nicolae Malaxa&quot; Clinical Hospital, Department of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>022441</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cluj Emergency Clinical County Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deva County Hospital, Department of Internal Medicine</name>
      <address>
        <city>Deva</city>
        <zip>330084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice &quot;Morosanu V. Magdalena&quot;</name>
      <address>
        <city>Galati</city>
        <zip>800371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Oradea</city>
        <zip>410032</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Diabmed Dr. Popescu Alexandrina SRL</name>
      <address>
        <city>Ploiesti</city>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satu Mare County Hospital, Department of Diabetology and Nutrition Diseases</name>
      <address>
        <city>Satu Mare</city>
        <zip>440055</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibiu Clinical County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sf. Ioan cel Nou&quot; Suceava Emergencency County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Suceava</city>
        <zip>720284</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice &quot;Dr. Gagiu Remus&quot;</name>
      <address>
        <city>Targoviste</city>
        <zip>130083</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare &quot;Kemerovo Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Endocrinology Scientific Center of the RAMS&quot;,</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Institution Public Corporation Polyclinic &quot;Gazprom&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117420</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Close Corporation &quot;MEDSI&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Continuing Professional Education &quot;Russian Medical Academy of Postgraduate Education of the Federal Agency of Health and Social Development&quot;, Chair of Endocrinology and Diabetology, Non-State Institution of Public Hea</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Clinic of New Medical Technologies&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>140091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Institution of Healthcare &quot;Novosibirsk State Regional Clinical Hospital&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Scientific Research Institute of Therapy of the Siberian Department of the Russian Academy of Medical Sciences</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Federal Center of Heart, Blood and Endocrinology named after V.A. Almazov&quot; of Federal Agency on High Technology Medical Care</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Center &quot;Diabetes&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Medical Institution &quot;City Outpatient Clinic # 20&quot; of Saratov Administration Healthcare</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of High Professional Education &quot;Smolensk State Medical Academy of Federal Agency of Healthcare and Social Development</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Medical-Military Academy named after S.M. Kirov, Clinic of Therapy of Postgraduate Education named after N.S. Molchanov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of High Professional Education &lt;Siberian State University of Federal Agency of Healthcare and Social Development</name>
      <address>
        <city>Tomsk</city>
        <zip>634034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Healthcare Clinical Ambulance Hospital named after N. V. Soloviev</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Isis Pharmaceuticals</name_title>
    <organization>Isis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

